Phos

AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis

AM Pharma Continues Its Success with Positive Phase IIa ClinicalTrial Results First clinical Results Confirm Potential New Application of KeyProduct in AM-Pharma's Pipeline BUNNIK, The Netherlands, July 9, 2007-AM-Pharma B.V., thebiopharmaceutical company developing novel therapeutics to treatinfectious and inflammatory diseases, today announced the positiveclinical results of its...

Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Company's Dermal Drug Delivery Technology

MELBOURNE, Australia, June 25, 2007 /PRNewswire-FirstCall/ --Phosphagenics Limited (AIM: PSG) announced today positive resultsfrom pre-clinical studies of its TPM-02 dermal drug deliverytechnology formulated with retinoic acid, a leading topicaltreatment for severe acne and an active ingredient used inanti-aging cosmetics. The proof of concept studies showed a three-fold increase i...

Neoprobe Phase 2 Lymphoseek Trial Meets Primary Endpoint

DUBLIN, Ohio--(BUSINESS WIRE)--Jun 20, 2007 - Neoprobe Corporation(OTCBB:NEOP), a diversified developer of innovative oncology andcardiovascular surgical and diagnostic products, today announcedpositive preliminary results from a multicenter Phase 2 clinicalstudy of its lead clinical candidate, Lymphoseek(R) (TechnetiumTc99m DTPA-mannosyl-dextran). Lymphoseek is a proprietaryradioactive tar...

Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics

Trophos Describes Identification, Characterization and BroadNeuroprotective Properties of TRO19622 in Journal of Pharmacologyand Experimental Therapeutics Neurodegenerative Disease Specialists Publish Details of a NovelDrug Candidate for ALS That Targets Mitochondrial Proteins MARSEILLE, June 19th, 2007 - Trophos SA, a biopharmaceuticalcompany specializing in the discovery an...

Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus

-LymphoStat-B(R) significantly reduced signs and symptoms of SLEdisease at 52 Weeks and demonstrated durable clinical andbiological activity at 76 weeks- ROCKVILLE, Md., June 14, 2007 /PRNewswire-FirstCall/ -- HumanGenome Sciences, Inc. today announced the presentation of Phase 2trial data demonstrating that LymphoStat-B(R) (belimumab)significantly reduced disease activity across multiple...

New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel

22 US Oncology Affiliated Physicians Participate in ASCOProceedings HOUSTON, June 04, 2007 /PRNewswire/ -- A leading cancerresearcher affiliated with the US Oncology Research Networkpresented findings from a randomized, multicenter phase III trialthat compared the disease-free survival (DFS) obtained with tworegimens of adjuvant therapy for patients with high-risk breastcancer. Th...

Phosphagenics to Commence Phase 1b Transdermal Insulin Clinical Trial in Second Quarter

MELBOURNE, Australia, May 03, 2007 /PRNewswire-FirstCall/ --Phosphagenics Limited (AIM: PSG) announced today that the Companyintends to initiate a Phase 1b clinical trial to demonstrate theefficacy and safety of the improved formulation of its transdermalinsulin product, TPM-02/Insulin, containing long-acting insulin.The trial is expected to commence in the second quarter of2007....

ACC Presentation Indicates Interleukin-1 Gene Variants Determine Increased Risk for Coronary Artery Disease from Oxidized Phospholipids

WALTHAM, Mass.--(BUSINESS WIRE)--Mar 27, 2007 - InterleukinGenetics, Inc. (AMEX:ILI) and collaborators at the University ofCalifornia San Diego today reported at the American College ofCardiology annual meeting that associations between coronary arterydisease (CAD) and both oxidized phospholipids (OxPL) and Lp(a)levels appear to be dependent on pro-inflammatory variants of theinterleukin-1...

AM-Pharma Announces Positive Results of a Phase IIa Clinical Trial with Alkaline Phosphatase in Acute Renal Failure

Results expand potential application of key product inAM-Pharma's pipeline BUNNIK, The Netherlands, 14 March, 2007. AM-Pharma B.V., thebiopharmaceutical company developing novel therapeutics to treatinfectious and inflammatory diseases, today announced positiveresults in patients with Acute Renal Failure. The patients involvedwere a subgroup of a Phase IIa trial with Alkaline Phosp...